1. Home
  2. CSTL vs CRF Comparison

CSTL vs CRF Comparison

Compare CSTL & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$32.44

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo Cornerstone Total Return Fund Inc. (The)

CRF

Cornerstone Total Return Fund Inc. (The)

N/A

Current Price

$7.68

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CSTL
CRF
Founded
2007
1973
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CSTL
CRF
Price
$32.44
$7.68
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$46.67
N/A
AVG Volume (30 Days)
407.5K
1.1M
Earning Date
02-26-2026
01-01-0001
Dividend Yield
N/A
18.10%
EPS Growth
N/A
N/A
EPS
N/A
1.40
Revenue
$343,530,000.00
$11,461,786.00
Revenue This Year
$2.88
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.38
Revenue Growth
10.15
6.53
52 Week Low
$14.59
$5.70
52 Week High
$44.28
$9.56

Technical Indicators

Market Signals
Indicator
CSTL
CRF
Relative Strength Index (RSI) 24.66 35.85
Support Level $38.20 $7.65
Resistance Level $40.88 $8.00
Average True Range (ATR) 1.98 0.09
MACD -1.10 -0.03
Stochastic Oscillator 3.79 31.17

Price Performance

Historical Comparison
CSTL
CRF

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.

Share on Social Networks: